{"nctId":"NCT01156571","briefTitle":"A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)","startDateStruct":{"date":"2010-09"},"conditions":["Atherosclerosis","Percutaneous Coronary Intervention","Acute Coronary Syndrome"],"count":11145,"armGroups":[{"label":"cangrelor","type":"EXPERIMENTAL","interventionNames":["Drug: cangrelor P2Y12 (platelet) inhibitor","Drug: Clopidogrel 600 mg post cangrelor"]},{"label":"clopidogrel","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Clopidogrel - 300 or 600 mg (study arm)"]}],"interventions":[{"name":"cangrelor P2Y12 (platelet) inhibitor","otherNames":[]},{"name":"Clopidogrel - 300 or 600 mg (study arm)","otherNames":[]},{"name":"Clopidogrel 600 mg post cangrelor","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPatients may be included in the study if they meet all of the following criteria:\n\n* Male or non-pregnant female at least 18 years of age\n* Patients undergoing percutaneous coronary intervention (PCI):\n\n  1. Stable angina (SA) patients with diagnostic coronary angiography within 90 days prior to randomization demonstrating atherosclerosis\n  2. Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) patients with diagnostic coronary angiography within 72 hours prior to randomization demonstrating atherosclerosis\n  3. ST-segment elevation myocardial infarction (STEMI) patients (diagnostic angiography not required)\n* Provide written informed consent\n\nExclusion Criteria:\n\nPatients will be excluded from the study if any of the following exclusion criteria apply prior to randomization:\n\n* Receipt of any P2Y12 inhibitor at any time in the 7 days preceding randomization\n* Eptifibatide and tirofiban usage within 12 hours preceding randomization (most recent dose must have been administered â‰¥12 hours prior to randomization)\n* Abciximab usage within 7 days preceding randomization\n* Receipt of fibrinolytic therapy in the 12 hours preceding randomization\n* Increased bleeding risk: ischemic stroke within the last year or any previous hemorrhagic stroke; tumor, cerebral arteriovenous malformation, or intracranial aneurysm; recent (\\<1 month) trauma or major surgery (including bypass surgery); currently receiving warfarin; active bleeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) and Stent Thrombosis (ST)","description":"Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat \\[mITT\\] population)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"257","spread":null},{"groupId":"OG001","value":"322","spread":null}]}]}]},{"type":"SECONDARY","title":"Individual Incidence of Stent Thrombosis (ST), Death, Myocardial Infarction (MI) and Ischemia-driven Revascularization (IDR)","description":"CEC-adjudicated results (mITT population)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"207","spread":null},{"groupId":"OG001","value":"255","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Major/Minor Non-coronary Artery Bypass Graft (CABG)-Related Hemorrhage by Clinical Relevant Criteria - GUSTO Severe/Life-threatening, Moderate and Mild","description":"GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":122,"n":5529},"commonTop":[]}}}